769169-02-0

Basic information

• Product Name: 2-Oxazolidinone, 4-(phenylmethyl)-3-(4,4,4-trifluoro-1-oxobutyl)-, (4R)-
• CAS NO: 769169-02-0
• Molecular Formula: C14H14F3NO3
• Molecular Weight: 301.265
• Mol File: 769169-02-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Oxazolidinone, 4-(phenylmethyl)-3-(4,4,4-trifluoro-1-oxobutyl)-, (4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxazolidinone, 4-(phenylmethyl)-3-(4,4,4-trifluoro-1-oxobutyl)-, (4R)-(769169-02-0)
• EPA Substance Registry System: 2-Oxazolidinone, 4-(phenylmethyl)-3-(4,4,4-trifluoro-1-oxobutyl)-, (4R)-(769169-02-0)

Safety Data

• Hazardous Substances Data: 769169-02-0(Hazardous Substances Data)

Upstream product

• 406-93-9 4,4,4-trifluorobutyric acid 
• 40217-17-2 (R)-4-(phenylmethyl)-2-oxazolidinone 
• 3282-30-2 pivaloyl chloride 

Downstream Products

• 769169-03-1 (4R)-4-benzyl-3-[(2R)-4,4,4-trifluoro-2-methylbutanoyl]-1,3-oxazolidin-2-one 

Relevant articles and documents

PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19)

Provided are USP19 inhibitors, methods of treating obesity, metabolic syndrome and/or diabetes using the USP19 inhibitor compounds, as well as those compounds for use in methods of treating obesity, metabolic syndrome and/or diabetes. Also provided are methods of treating muscular atrophy, for example cachexia or sarcopenia with USP19 inhibitor compounds, plus those compounds for use in methods of treating muscular atrophy.

PHARMACEUTICAL COMPOUNDS

The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.

Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof

Compounds of Formula (I), are provided where T is CHO, CON, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y═C, or substituted diene fused to Y when Y═C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.